PB2117: TALQUETAMAB VS REAL-WORLD PHYSICIAN’S CHOICE OF THERAPY: COMPARATIVE EFFECTIVENESS IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA

• Jing Christine Ye,
• Noa Biran,
• Sandhya Nair,
• Xiwu Lin,
• Keqin Qi,
• Anil Londhe,
• Eric Ammann,
• Thomas Renaud,
• Colleen Kane,
• Trilok Parekh,
• Kathleen Gray,
• Steve Peterson,
• Luciano Costa

Affiliations

Jing Christine Ye

1 University of Michigan, Rogel Cancer Center at the time that the work was performed, Ann Arbor, United States

Noa Biran

2 Hackensack University Medical Center, Hackensack, United States

Sandhya Nair

3 Janssen Pharmaceutica NV, Beerse, Belgium

Xiwu Lin

4 Janssen Global Services, Horsham, United States

Keqin Qi

5 Janssen Research & Development, Titusville, United States

Anil Londhe

5 Janssen Research & Development, Titusville, United States

Eric Ammann

6 Janssen Global Services, Raritan, United States

Thomas Renaud

7 Janssen Research & Development, Raritan, United States

Colleen Kane

8 Janssen Research & Development, Spring House, United States

Trilok Parekh

9 Janssen Research & Development, Bridgewater, United States

Kathleen Gray

8 Janssen Research & Development, Spring House, United States

Steve Peterson

10 Janssen Research & Development, Horsham

Luciano Costa

11 University of Alabama at Birmingham, Birmingham, United States